MYO · MYOMO, INC.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $1.11 |
| SO | 38.6M |
| Options | 0.0M |
| Warrants | 5.1M |
| FD SO | 43.8M |
| MC | $48.6M |
| Cash | $11.4M |
| Total debt | $10.9M |
| EV | $48.1M |
| TTM Multiples | |
|---|---|
| EV / Revenue | 1.2x |
| EV / EBITDA | — |
| MC / Net Income | — |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 41.0% |
| Insiders | 9.1% |
| # Institutions | 104 |
| Analysts | 5 |
| Consensus | — |
| Avg target | $4.42 |
| Short % float | 7.2% |
| Days to cover | 1.63 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-01. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Total Revenue | 10.11 | 11.35 | 10.09 | 9.65 |
| Revenue YoY % | 2.9% | (5.9%) | 9.6% | 28.3% |
| Cost of Revenue | 3.21 | 3.57 | 3.65 | 3.60 |
| Gross Profit | 6.90 | 7.78 | 6.44 | 6.05 |
| Gross Profit YoY % | 4.4% | (9.6%) | (7.2%) | 13.6% |
| Gross Margin % | 68.2% | 68.6% | 63.8% | 62.7% |
| SG&A | 8.44 | 8.93 | 8.43 | 8.64 |
| R&D | 1.62 | 1.62 | 1.53 | 2.00 |
| Operating Expense | 10.06 | 10.56 | 9.96 | 10.64 |
| Operating Income | (3.16) | (2.77) | (3.52) | (4.59) |
| Operating Income YoY % | 10.3% | (1030.7%) | (267.3%) | (311.7%) |
| Operating Margin % | (31.2%) | (24.4%) | (34.9%) | (47.6%) |
| EBITDA | (2.87) | (2.51) | (3.27) | (4.40) |
| EBITDA Margin % | (28.3%) | (22.1%) | (32.4%) | (45.6%) |
| Other Income / (Expense) | — | (0.96) | — | — |
| Pretax Income | (2.82) | (3.73) | (3.53) | (4.48) |
| Tax Provision | 0.19 | 0.08 | 0.14 | 0.15 |
| Net Income | (3.01) | (3.81) | (3.66) | (4.63) |
| Net Income to Common | (3.01) | (3.84) | (3.66) | (4.63) |
| Net Margin % | (29.8%) | (33.6%) | (36.3%) | (48.0%) |
| Diluted EPS | -$0.07 | -$0.09 | -$0.09 | -$0.11 |
| Basic EPS | -$0.07 | -$0.09 | -$0.09 | -$0.11 |
| Diluted Avg Shares | 42.3 | — | 42.2 | 41.6 |
| Basic Avg Shares | 42.3 | — | 42.2 | 41.6 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Total Revenue | 41.21 | 40.93 | 32.55 | 19.24 | 15.56 |
| Revenue YoY % | 0.7% | 25.7% | 69.2% | 23.7% | — |
| Cost of Revenue | 14.03 | 14.04 | 9.37 | 6.06 | 5.30 |
| Gross Profit | 27.18 | 26.89 | 23.19 | 13.18 | 10.25 |
| Gross Profit YoY % | 1.1% | 16.0% | 75.9% | 28.6% | — |
| Gross Margin % | 66.0% | 65.7% | 71.2% | 68.5% | 65.9% |
| SG&A | 34.44 | 34.35 | 24.62 | 18.78 | 18.44 |
| R&D | 6.78 | 6.94 | 4.77 | 2.64 | 2.48 |
| Operating Expense | 41.22 | 41.29 | 29.39 | 21.41 | 20.93 |
| Operating Income | (14.04) | (14.40) | (6.21) | (8.23) | (10.67) |
| Operating Income YoY % | 2.5% | (132.0%) | 24.6% | 22.9% | — |
| Operating Margin % | (34.1%) | (35.2%) | (19.1%) | (42.8%) | (68.6%) |
| EBITDA | (13.05) | (13.54) | (6.00) | (8.07) | (10.48) |
| EBITDA Margin % | (31.7%) | (33.1%) | (18.4%) | (41.9%) | (67.4%) |
| Other Income / (Expense) | (0.53) | (0.67) | — | — | — |
| Pretax Income | (14.56) | (15.07) | (5.82) | (7.99) | (10.65) |
| Tax Provision | 0.55 | 0.50 | 0.37 | 0.16 | 0.07 |
| Net Income | (15.12) | (15.57) | (6.18) | (8.15) | (10.72) |
| Net Income to Common | (15.14) | (15.60) | (6.20) | (8.10) | (10.72) |
| Net Margin % | (36.7%) | (38.1%) | (19.0%) | (42.3%) | (68.9%) |
| Diluted EPS | -$0.36 | -$0.37 | -$0.16 | -$0.28 | -$1.52 |
| Basic EPS | -$0.36 | -$0.37 | -$0.16 | -$0.28 | -$1.52 |
| Diluted Avg Shares | 42.3 | 41.9 | 37.8 | 29.5 | 7.1 |
| Basic Avg Shares | 42.3 | 41.9 | 37.8 | 29.5 | 7.1 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 11.40 | 14.13 | 12.55 | 14.24 |
| Short-term Investments | 4.30 | 4.26 | 0.00 | 1.24 |
| Receivables | 4.82 | 4.10 | 5.29 | 7.05 |
| Inventory | 3.55 | 3.12 | 3.65 | 4.13 |
| Other Current Assets | 1.59 | 1.94 | 1.46 | 1.38 |
| Total Current Assets | 25.66 | 27.56 | 22.95 | 28.04 |
| Net PPE | 2.24 | 2.21 | 3.71 | 2.91 |
| Operating Lease ROU | 6.50 | 6.68 | 6.87 | 7.06 |
| Other Assets | 2.35 | 2.19 | 0.54 | 0.66 |
| Total Assets | 36.75 | 38.64 | 34.08 | 38.67 |
| Current Debt | 2.73 | 2.73 | 0.58 | 0.17 |
| Current Lease Liabilities | 0.59 | 0.49 | 0.46 | 0.46 |
| Other Current Liabilities | 6.06 | 5.12 | 8.15 | 11.13 |
| Total Current Liabilities | 9.39 | 8.35 | 9.20 | 11.75 |
| Long-term Debt | 10.93 | 11.22 | 2.42 | 1.33 |
| Long-term Lease Liabilities | 7.44 | 7.67 | 7.83 | 7.97 |
| Total Liabilities | 27.75 | 27.23 | 19.45 | 21.06 |
| Retained Earnings | (121.70) | (118.69) | (114.87) | (111.21) |
| Total Equity | 9.00 | 11.40 | 14.63 | 17.62 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.40 | 14.13 | 24.37 | 6.87 | 5.35 |
| Short-term Investments | 4.30 | 4.26 | 0.49 | 1.99 | 0.00 |
| Receivables | 4.82 | 4.10 | 3.83 | 2.38 | 1.90 |
| Inventory | 3.55 | 3.12 | 3.17 | 1.80 | 1.40 |
| Other Current Assets | 1.59 | 1.94 | 0.93 | 0.60 | 0.57 |
| Total Current Assets | 25.66 | 27.56 | 32.79 | 13.65 | 9.22 |
| Net PPE | 2.24 | 2.21 | 1.33 | 0.18 | 0.19 |
| Operating Lease ROU | 6.50 | 6.68 | 7.58 | 0.66 | 0.51 |
| Other Assets | 2.35 | 2.19 | 0.54 | — | — |
| Total Assets | 36.75 | 38.64 | 42.24 | 14.58 | 10.16 |
| Current Debt | 2.73 | 2.73 | 2.95 | — | — |
| Current Lease Liabilities | 0.59 | 0.49 | 0.75 | 0.49 | 0.35 |
| Other Current Liabilities | 6.06 | 5.12 | 6.47 | 4.99 | 3.25 |
| Total Current Liabilities | 9.39 | 8.35 | 10.17 | 5.48 | 3.60 |
| Long-term Debt | 10.93 | 11.22 | — | — | — |
| Long-term Lease Liabilities | 7.44 | 7.67 | 7.36 | 0.12 | 0.20 |
| Total Liabilities | 27.75 | 27.23 | 17.53 | 5.59 | 3.80 |
| Retained Earnings | (121.70) | (118.69) | (103.11) | (96.93) | (88.78) |
| Total Equity | 9.00 | 11.40 | 24.71 | 8.99 | 6.36 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | (3.01) | (3.81) | (3.66) | (4.63) |
| D&A | 0.29 | 0.26 | 0.25 | 0.19 |
| Stock-Based Comp | 0.60 | 0.56 | 0.58 | 0.39 |
| Δ Working Cap & Other | (0.08) | 1.85 | 1.00 | (4.82) |
| Operating Cash Flow | (2.20) | (1.14) | (1.83) | (8.87) |
| CapEx | (0.33) | 1.24 | (1.05) | (1.26) |
| Other Investing | — | (5.83) | 1.24 | 0.50 |
| Investing Cash Flow | (0.49) | (4.59) | 0.19 | (0.76) |
| Debt Issuance | — | 0.00 | (1.00) | — |
| Other Financing | — | 7.51 | 0.95 | 4.00 |
| Financing Cash Flow | 0.00 | 7.51 | (0.05) | 4.00 |
| Free Cash Flow | (2.53) | 0.10 | (2.88) | (10.12) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Net Income | (15.12) | (15.57) | (6.18) | (8.15) | (10.72) |
| D&A | 0.99 | 0.86 | 0.21 | 0.16 | 0.19 |
| Stock-Based Comp | 2.14 | 2.08 | 0.87 | 1.12 | 1.19 |
| Δ Working Cap & Other | (2.05) | (1.88) | 1.81 | 0.69 | (0.90) |
| Operating Cash Flow | (14.03) | (14.51) | (3.29) | (6.17) | (10.23) |
| CapEx | (1.40) | (1.74) | (1.36) | (0.15) | (0.11) |
| Other Investing | (4.26) | (5.32) | 1.62 | (1.88) | — |
| Investing Cash Flow | (5.66) | (7.06) | 0.26 | (2.03) | (0.31) |
| Debt Issuance | — | 3.00 | 0.00 | — | — |
| Debt Repayment | — | (4.00) | 0.00 | — | — |
| Other Financing | 11.46 | 12.43 | 20.93 | 9.71 | — |
| Financing Cash Flow | 11.46 | 11.43 | 20.93 | 9.71 | 0.38 |
| Free Cash Flow | (15.43) | (16.25) | (4.65) | (6.32) | (10.35) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 2.73 | 3.30 | 2.49 | 2.39 |
| Quick Ratio | 2.36 | 2.93 | 2.10 | 2.03 |
| Debt / Equity | 3.08 | 2.39 | 1.33 | 1.20 |
| EBITDA Margin % | (28.3%) | (22.1%) | (32.4%) | (45.6%) |
| Working Capital | 16.27 | 19.21 | 13.75 | 16.29 |
| Net Debt | (0.47) | (2.91) | (10.14) | (12.91) |
| ROE % | (33.4%) | (33.4%) | (25.0%) | (26.3%) |
| ROA % | (8.2%) | (9.9%) | (10.7%) | (12.0%) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Current Ratio | 2.73 | 3.30 | 3.22 | 2.49 | 2.56 |
| Quick Ratio | 2.36 | 2.93 | 2.91 | 2.16 | 2.17 |
| Debt / Equity | 3.08 | 2.39 | 0.71 | 0.62 | 0.60 |
| EBITDA Margin % | (31.7%) | (33.1%) | (18.4%) | (41.9%) | (67.4%) |
| Working Capital | 16.27 | 19.21 | 22.62 | 8.17 | 5.61 |
| Net Debt | (0.47) | (2.91) | — | — | — |
| ROE % | (167.9%) | (136.6%) | (25.0%) | (90.6%) | (168.6%) |
| ROA % | (41.1%) | (40.3%) | (14.6%) | (55.9%) | (105.5%) |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Mitchell Micah | Officer (Chief Commercial Officer) | 2026-06-08 | F | (6,529) | $1.33 | -$8,684 |
| 2026-06-09 | Kovelman Harry | Officer (Chief Medical Officer) | 2026-06-08 | F | (7,635) | $1.33 | -$10,155 |
| 2026-06-09 | HENRY DAVID A | Officer (Chief Financial Officer) | 2026-06-08 | F | (10,050) | — | $-0 |
| 2026-06-09 | KIRK THOMAS F | Director | 2026-06-05 | P | 40,002 | $1.27 | $50,803 |
| 2026-06-08 | Mitchell Micah | Officer (Chief Commercial Officer) | 2026-05-14 | S | (90,231) | $0.86 | -$77,689 |
| 2026-06-01 | KIRK THOMAS F | Director | 2026-05-28 | P | 25,000 | $0.99 | $24,825 |
| 2026-05-28 | Kovelman Harry | Officer (Chief Medical Officer) | 2026-05-28 | S | (11,536) | $1.02 | -$11,734 |
| 2026-05-28 | Kovelman Harry | Officer (Chief Medical Officer) | 2026-05-27 | S | (20,464) | $1.00 | -$20,505 |
| 2026-05-18 | KIRK THOMAS F | Director | 2026-05-18 | P | 43,401 | $0.91 | $39,495 |
| 2026-05-18 | KIRK THOMAS F | Director | 2026-05-15 | P | 31,605 | $0.91 | $28,748 |
| 2026-05-18 | Manko Joseph M. Jr. | Director | 2026-05-15 | P | 30,367 | $0.89 | $26,960 |
| 2026-05-18 | Manko Joseph M. Jr. | Director | 2026-05-14 | P | 170,830 | $0.86 | $146,948 |
| 2026-05-15 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-05-14 | S | (90,231) | $0.86 | -$77,689 |
| 2026-04-16 | FEBBO WILLIAM J | Director | 2026-04-14 | A | 45,000 | — | $0 |
| 2026-04-14 | HENRY DAVID A | Officer (Chief Financial Officer) | 2026-04-13 | F | (3,953) | $0.71 | -$2,807 |
| 2026-04-14 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2026-04-10 | A | 16,666 | — | $0 |
| 2026-04-14 | HENRY DAVID A | Officer (Chief Financial Officer) | 2026-04-10 | A | 12,500 | — | $0 |
| 2026-04-14 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2026-04-10 | A | 19,395 | — | $0 |
| 2026-03-17 | Getz Heather C | Director | 2026-03-16 | P | 20,000 | $0.70 | $13,972 |
| 2026-03-16 | KIRK THOMAS F | Director | 2026-03-13 | P | 72,000 | $0.71 | $51,113 |
| 2026-03-12 | Getz Heather C | Director | 2026-03-12 | P | 70,000 | $0.73 | $50,960 |
| 2026-01-14 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2026-01-12 | A | 11,637 | — | $0 |
| 2026-01-14 | HENRY DAVID A | Officer (Chief Financial Officer) | 2026-01-12 | A | 8,727 | — | $0 |
| 2025-11-24 | KIRK THOMAS F | Director | 2025-11-21 | P | 2,535 | $0.72 | $1,825 |
| 2025-11-24 | KIRK THOMAS F | Director | 2025-11-20 | P | 4,902 | $0.72 | $3,529 |
| 2025-11-21 | Crowley Thomas Aloysius Jr. | Director | 2025-11-19 | P | 385 | $0.77 | $295 |
| 2025-11-21 | Crowley Thomas Aloysius Jr. | Director | 2025-11-18 | P | 4,000 | $0.73 | $2,938 |
| 2025-09-11 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-09-09 | G | (10,000) | — | $-0 |
| 2025-08-26 | KIRK THOMAS F | Director | 2025-08-25 | P | 50,000 | $1.15 | $57,500 |
| 2025-08-19 | KIRK THOMAS F | Director | 2025-08-18 | P | 50,000 | $1.10 | $55,000 |
| 2025-08-18 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-08-15 | P | 50,000 | $0.95 | $47,295 |
| 2025-07-02 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-06-30 | F | (13,054) | $2.19 | -$28,588 |
| 2025-07-02 | HENRY DAVID A | Officer (Chief Financial Officer) | 2025-06-30 | F | (23,587) | $2.19 | -$51,656 |
| 2025-06-13 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-06-11 | A | 62,938 | — | $0 |
| 2025-06-13 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-06-11 | A | 59,440 | — | $0 |
| 2025-06-13 | HENRY DAVID A | Officer (Chief Financial Officer) | 2025-06-11 | A | 76,398 | — | $0 |
| 2025-06-13 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-06-11 | A | 157,342 | — | $0 |
| 2025-06-12 | KIRK THOMAS F | Director | 2025-06-11 | A | 29,720 | — | $0 |
| 2025-06-12 | Crowley Thomas Aloysius Jr. | Director | 2025-06-11 | A | 29,720 | — | $0 |
| 2025-06-12 | Morris Milton Mayo | Director | 2025-06-11 | A | 29,720 | — | $0 |
| 2025-06-12 | Getz Heather C | Director | 2025-06-11 | A | 29,720 | — | $0 |
| 2025-06-06 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-06-06 | F | (5,743) | $2.97 | -$17,057 |
| 2025-06-06 | HENRY DAVID A | Officer (Chief Financial Officer) | 2025-06-06 | F | (8,373) | $2.97 | -$24,868 |
| 2025-05-15 | KIRK THOMAS F | Director | 2025-05-15 | P | 36,824 | $3.25 | $119,678 |
| 2025-05-15 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-05-15 | P | 30,000 | $3.22 | $96,612 |
| 2025-05-15 | KIRK THOMAS F | Director | 2025-05-14 | P | 1,943 | $3.25 | $6,315 |
| 2025-05-14 | KIRK THOMAS F | Director | 2025-05-12 | P | 50,000 | $3.35 | $167,500 |
| 2025-03-21 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-14 | S | (48,000) | $5.16 | -$247,565 |
| 2025-03-14 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-14 | S | (48,000) | $5.16 | -$247,565 |
| 2025-03-14 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-14 | S | (48,000) | $5.16 | -$247,565 |
| 2025-03-14 | KIRK THOMAS F | Director | 2025-03-13 | P | 7,400 | $5.00 | $37,000 |
| 2025-03-14 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-13 | F | (1,283) | $5.22 | -$6,697 |
| 2025-03-14 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-11 | A | 3,737 | — | $0 |
| 2025-03-13 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-03-13 | F | (1,496) | $5.22 | -$7,809 |
| 2025-03-13 | HENRY DAVID A | Officer (Chief Financial Officer) | 2025-03-13 | F | (2,019) | $5.22 | -$10,539 |
| 2025-03-13 | Mitchell Micah | Officer (Chief Commercial Officer) | 2025-03-13 | F | (1,283) | $5.22 | -$6,697 |
| 2025-03-13 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-03-12 | S | (30,000) | $5.50 | -$165,018 |
| 2025-03-13 | Kovelman Harry | Officer (Chief Medical Officer) | 2025-03-11 | A | 3,553 | — | $0 |
| 2025-03-13 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-03-11 | A | 6,708 | — | $0 |
| 2025-03-13 | HENRY DAVID A | Officer (Chief Financial Officer) | 2025-03-11 | A | 4,106 | — | $0 |
| 2025-03-13 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-03-11 | A | 3,737 | — | $0 |
| 2025-02-18 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-02-13 | M | 694 | $0.05 | $33 |
| 2025-02-18 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2025-02-13 | M | (694) | — | $-0 |
| 2025-01-24 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-06-09 | M | 1,717 | — | $0 |
| 2025-01-24 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-06-09 | M | (1,717) | — | $-0 |
| 2025-01-24 | HENRY DAVID A | Officer (Chief Financial Officer) | 2024-06-09 | M | 3,012 | — | $0 |
| 2025-01-24 | HENRY DAVID A | Officer (Chief Financial Officer) | 2024-06-09 | M | (3,012) | — | $-0 |
| 2025-01-24 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-06-09 | M | 1,235 | — | $0 |
| 2025-01-24 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-06-09 | M | (1,235) | — | $-0 |
| 2025-01-24 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2024-06-09 | M | 6,024 | — | $0 |
| 2025-01-24 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2024-06-09 | M | (6,024) | — | $-0 |
| 2025-01-22 | GUDONIS PAUL R | Director, Officer (Chief Executive Officer) | 2024-06-05 | A | 130,000 | — | $0 |
| 2024-11-05 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-11-04 | F | (121) | $3.70 | -$448 |
| 2024-10-04 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-10-03 | F | (121) | $3.86 | -$467 |
| 2024-09-09 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-09-05 | S | (6,700) | $3.76 | -$25,183 |
| 2024-09-05 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-09-04 | F | (139) | $3.89 | -$541 |
| 2024-09-05 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-09-03 | S | (2,029) | $4.01 | -$8,140 |
| 2024-08-07 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-08-05 | F | (128) | $3.96 | -$507 |
| 2024-07-08 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-07-03 | F | (121) | $2.85 | -$345 |
| 2024-07-02 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-07-01 | F | (15,500) | $3.02 | -$46,810 |
| 2024-07-02 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-07-01 | F | (12,868) | $3.02 | -$38,861 |
| 2024-07-02 | HENRY DAVID A | Officer (Chief Financial Officer) | 2024-07-01 | F | (25,436) | $3.02 | -$76,817 |
| 2024-07-02 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-06-10 | F | (6,837) | $3.38 | -$23,089 |
| 2024-07-02 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-06-10 | F | (5,347) | $3.38 | -$18,068 |
| 2024-06-12 | HENRY DAVID A | Officer (Chief Financial Officer) | 2024-06-10 | F | (10,620) | $3.38 | -$35,853 |
| 2024-06-12 | Kovelman Harry | Officer (Chief Medical Officer) | 2024-06-10 | F | 5,347 | $3.38 | $18,068 |
| 2024-06-12 | Mitchell Micah | Officer (Chief Commercial Officer) | 2024-06-10 | F | 6,837 | $3.38 | $23,089 |